Home>Topics>Companies>Novartis

Novartis NVS

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Novartis digs into health tech with bet on "robotic pill"

      Headlines

      Wed, 27 May 2015

      LONDON, May 27 (Reuters) - Swiss drugmaker Novartis is raising its bet on smart technology by collaborating with U.S. start-up Rani Therapeutics on a "robotic pill" for complex biotech drugs that would normally have to be given by injection.

    2. BRIEF- Novartis to present new data at ASCO and EHA

      Headlines

      Wed, 27 May 2015

      * Says to present new data on 21 medicines and 11 investigational compounds at ASCO and EHA Further company coverage: (Reporting By Zurich Slot)

    3. BRIEF- Novartis says Afinitor extended life in some tumor patients

      Headlines

      Thu, 21 May 2015

      * Novartis international AG says Afinitor extended progression-free survival in phase iii trial in advanced gastrointestinal or lung neuroendocrine tumors Further company coverage: (Reporting By Zurich Slot)

    4. BRIEF- Novartis says lung disease drug studies show positive results

      Headlines

      Wed, 20 May 2015

      * Novartis says it saw positive results from two Phase III clinical trial programs for QVA149 and NVA237 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

    5. Abdominal Aortic Aneurysms Global Market Clinical Trials Review, H1, 2015 research Reports

      Commentary

      Wed, 13 May 2015

      Trials 28 Prominent Drugs 29 Clinical Trial Profiles 30 Clinical Trial Overview of Top Companies 30 Novartis AG 30 Clinical Trial Overview of Novartis AG 30 Sanofi 31 Clinical Trial Overview of Sanofi 31 Fresenius Kabi AG 32 Clinical Trial Overview

    6. Novartis says lung cancer drug Zykadia gains EU approval

      Headlines

      Fri, 8 May 2015

      ZURICH, May 8 (Reuters) - Swiss drugmaker Novartis said European health regulators have approved a drug for advanced lung cancer that is intended to treat patients with a specific genetic mutation.

    7. UPDATE 1- Novartis 'biosimilar' drug blocked by U.S. appeals court

      Headlines

      Thu, 7 May 2015

      May 7 (Reuters) - A U.S. appeals court has blocked the sale of Novartis AG 's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients.

    8. Novartis AG's 'biosimilar' drug sale blocked by U.S. appeals court

      Headlines

      Thu, 7 May 2015

      May 7 (Reuters) - A U.S. appeals court has blocked the sale of Novartis AG 's recently approved "biosimilar" form of Neupogen, Amgen Inc's blockbuster drug used to prevent infections in cancer...

    9. Vanda's Hetlioz Launch Continues to Progress; Maintaining Fair Value Estimate

      Commentary

      Thu, 7 May 2015

      which increased from $6.0 million last quarter. Fanapt sales were $14.7 million following the recent deal with Novartis to return the U.S. and Canadian rights for the schizophrenia drug to Vanda. These results are trending toward guidance

    10. BRIEF-Oxford Biomedica says "actively" looking for more technology licensing deals

      Headlines

      Thu, 7 May 2015

      * Will continue to expand physical capacity during 2015 and in first half of 2016 to ensure can meet deliverables under Novartis contract

    « Prev12345Next »
    Content Partners